4//SEC Filing
ALLERGAN INC 4
Accession 0001127602-15-012133
CIK 0000850693operating
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:45 PM ET
Size
30.4 KB
Accession
0001127602-15-012133
Insider Transaction Report
Form 4
ALLERGAN INCAGN
PYOTT DAVID E I
DirectorChairman and CEO
Transactions
- Gift
Common Stock
2015-02-12−114,548→ 114,548 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2015-03-17−165,658.141→ 0 total - Disposition to Issuer
Common Stock
2015-03-17−2,180.28→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2015-03-17−2,896.936→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2015-03-17−114,548→ 0 total(indirect: By Trust) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−386,800→ 0 total(indirect: By Trust)Exercise: $58.55Exp: 2017-02-02→ Common Stock (386,800 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−410,000→ 0 total(indirect: By Trust)Exercise: $64.47Exp: 2018-02-14→ Common Stock (410,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−375,000→ 0 total(indirect: By Trust)Exercise: $75.58Exp: 2021-02-17→ Common Stock (375,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−312,000→ 0 total(indirect: By Trust)Exercise: $87.91Exp: 2022-02-17→ Common Stock (312,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−533,000→ 0 total(indirect: By Trust)Exercise: $40.16Exp: 2019-02-20→ Common Stock (533,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−422,400→ 0 total(indirect: By Trust)Exercise: $59.13Exp: 2020-02-22→ Common Stock (422,400 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−303,000→ 0 total(indirect: By Trust)Exercise: $105.87Exp: 2023-02-21→ Common Stock (303,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-03-17−257,756→ 0 total(indirect: By Trust)Exercise: $125.07Exp: 2024-02-21→ Common Stock (257,756 underlying)
Footnotes (5)
- [F1]Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis) and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for $129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of $307.51 per share on the Effective Date.
- [F2]Includes 165,000 performance-based restricted stock units ("RSUs") previously reported on Form 4 filed on February 22, 2012. The RSUs vested in full on the Effective date pursuant to the terms of the Merger Agreement.
- [F3]Includes shares acquired under the Allergan, Inc. Dividend Reinvestment Plan.
- [F4]The option was previously reported as covering 193,400 shares at an exercise price of $117.10. The shares reported herein reflect a two-for-one stock split effected by the Issuer on June 22, 2007.
- [F5]Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times $294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus $129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.
Documents
Issuer
ALLERGAN INC
CIK 0000850693
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000850693
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 7:45 PM ET
- Size
- 30.4 KB